2022-01816. Bulk Manufacturer of Controlled Substances Application: Siegfried USA, LLC  

  • Start Preamble

    AGENCY:

    Drug Enforcement Administration, Justice.

    ACTION:

    Notice of application.

    SUMMARY:

    Siegfried USA, LLC. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

    DATES:

    Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before April 1, 2022 Such persons may also file a written request for a hearing on the application on or before April 1, 2022.

    ADDRESSES:

    Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

    End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    In accordance with 21 CFR 1301.33(a), this is notice that on December 8, 2021, Siegfried USA, LLC., 33 Industrial Park Road, Pennsville, New Jersey 08070-3244, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

    Controlled substanceDrug codeSchedule
    Gamma Hydroxybutyric Acid2010I
    Dihydromorphine9145I
    Hydromorphinol9301I
    Amphetamine1100II
    Lisdexamfetamine1205II
    Methylphenidate1724II
    Amobarbital2125II
    Pentobarbital2270II
    Secobarbital2315II
    Phenylacetone8501II
    Codeine9050II
    Oxycodone9143II
    Hydromorphone9150II
    Hydrocodone9193II
    Methadone9250II
    Methadone intermediate9254II
    Morphine9300II
    Oripavine9330II
    Thebaine9333II
    Opium tincture9630II
    Oxymorphone9652II
    Tapentadol9780II

    The company plans to manufacture the above-listed controlled substance in bulk for development of a new active pharmaceutical ingredient (API) and validation for a Drug Master File submission to the Food and Drug Administration. No other activity for this drug code is authorized for this registration.

    Start Signature

    Brian S. Besser,

    Acting Assistant Administrator.

    End Signature End Supplemental Information

    [FR Doc. 2022-01816 Filed 1-28-22; 8:45 am]

    BILLING CODE P

Document Information

Published:
01/31/2022
Department:
Drug Enforcement Administration
Entry Type:
Notice
Action:
Notice of application.
Document Number:
2022-01816
Dates:
Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before April 1, 2022 Such persons may also file a written request for a hearing on the application on or before April 1, 2022.
Pages:
4941-4941 (1 pages)
Docket Numbers:
Docket No. DEA-947
PDF File:
2022-01816.pdf